Nicholas Conrad Smith net worth and biography

Nicholas Smith Biography and Net Worth

CFO of Alto Neuroscience

Nick Smith has served as our Chief Financial Officer since November 2022 and has served as our Chief Business Officer since September 2021. Mr. Smith also served as a member of our board of directors from July 2023 through October 2023. Prior to joining us, Mr. Smith served in various roles at Aptinyx Inc., a CNS-focused biopharmaceutical company, from March 2017 until September 2021, including Vice President, Investor Relations and Corporate Development from March 2021 to September 2021; Senior Director, Corporate Development and Investor Relations from March 2019 to March 2021; and Director, Corporate Development from March 2017 to March 2019. Mr. Smith received a BA in accounting and finance from North Central College.

What is Nicholas Conrad Smith's net worth?: The estimated net worth of Nicholas Conrad Smith is at least $528.43 thousand as of September 29th, 2026. Smith owns 24,060 shares of Alto Neuroscience stock worth more than $528,430 as of October 25th. This net worth evaluation does not reflect any other investments that Smith may own. Learn More about Nicholas Conrad Smith's net worth.
How do I contact Nicholas Conrad Smith?: The corporate mailing address for Smith and other Alto Neuroscience executives is 650 Castro Street, Suite 450, Mountain View, CA, 94041. Alto Neuroscience can also be reached via phone at (773) 255-5012 and via email at [email protected]. Learn More on Nicholas Conrad Smith's contact information.
Has Nicholas Conrad Smith been buying or selling shares of Alto Neuroscience?: Nicholas Conrad Smith has not been actively trading shares of Alto Neuroscience during the last quarter. Most recently, Nicholas Conrad Smith sold 24,056 shares of the business's stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $25.82, for a transaction totalling $621,125.92. Following the completion of the sale, the chief financial officer now directly owns 24,060 shares of the company's stock, valued at $621,229.20. Learn More on Nicholas Conrad Smith's trading history.
Who are Alto Neuroscience's active insiders?: Alto Neuroscience's insider roster includes Adam Savitz (Insider), and Nicholas Smith (CFO). Learn More on Alto Neuroscience's active insiders.
Are insiders buying or selling shares of Alto Neuroscience?: During the last year, insiders at the sold shares 2 times. They sold a total of 134,886 shares worth more than $3,566,987.32. The most recent insider tranaction occured on September, 30th when CFO Nicholas Conrad Smith sold 24,056 shares worth more than $621,125.92. Insiders at Alto Neuroscience own 11.3% of the company. Learn More about insider trades at Alto Neuroscience.
Information on this page was last updated on 9/30/2026.

Nicholas Conrad Smith Insider Trading History at Alto Neuroscience

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/30/2026	Sell	24,056	$25.82	$621,125.92	24,060
9/29/2026	Sell	110,830	$26.58	$2,945,861.40	24,060
3/28/2024	Buy	6,150	$16.36	$100,614.00	26,866

Nicholas Conrad Smith Buying and Selling Activity at Alto Neuroscience

Alto Neuroscience Company Overview

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Today's Range

Now: $21.96

$21.45

$22.45

50 Day Range

MA: $29.45

$21.70

$36.75

2 Week Range

Now: $21.96

$10.20

$37.48

Volume

379,246 shs

Average Volume

680,868 shs

Market Capitalization

$861.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31